158 related articles for article (PubMed ID: 21371244)
1. Benign prostatic hyperplasia: racial differences in treatment patterns and prostate cancer prevalence.
Pettaway CA; Lamerato LE; Eaddy MT; Edwards JK; Hogue SL; Crane MM
BJU Int; 2011 Oct; 108(8):1302-8. PubMed ID: 21371244
[TBL] [Abstract][Full Text] [Related]
2. Associations between diabetes and clinical markers of benign prostatic hyperplasia among community-dwelling Black and White men.
Sarma AV; Burke JP; Jacobson DJ; McGree ME; St Sauver J; Girman CJ; Lieber MM; Herman W; Macoska J; Montie JE; Jacobsen SJ
Diabetes Care; 2008 Mar; 31(3):476-82. PubMed ID: 18071006
[TBL] [Abstract][Full Text] [Related]
3. Potential selection bias in a community-based study of PSA levels in African-American men.
Heeringa SG; Alcser KH; Doerr K; Strawderman M; Cooney K; Medbery B; Schottenfeld D
J Clin Epidemiol; 2001 Feb; 54(2):142-8. PubMed ID: 11166529
[TBL] [Abstract][Full Text] [Related]
4. Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. PLESS Study Group.
Roehrborn CG; McConnell JD; Lieber M; Kaplan S; Geller J; Malek GH; Castellanos R; Coffield S; Saltzman B; Resnick M; Cook TJ; Waldstreicher J
Urology; 1999 Mar; 53(3):473-80. PubMed ID: 10096369
[TBL] [Abstract][Full Text] [Related]
5. Differences between African American and Caucasian men participating in a community-based prostate cancer screening program.
Barber KR; Shaw R; Folts M; Taylor DK; Ryan A; Hughes M; Scott V; Abbott RR
J Community Health; 1998 Dec; 23(6):441-51. PubMed ID: 9824793
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and tolerability of the dual 5alpha-reductase inhibitor, dutasteride, in the treatment of benign prostatic hyperplasia in African-American men.
Roehrborn CG; Ray P
Prostate Cancer Prostatic Dis; 2006; 9(4):432-8. PubMed ID: 16983393
[TBL] [Abstract][Full Text] [Related]
7. [The changes of prostate specific antigen (PSA) after treatment with alpha 1-adrenergic receptor antagonists in men with 4.0-9.9 ng/ml PSA level--a study for comparison of benign prostatic hyperplasia/lower urinary tract symptom (BPH/LUTS) and prostate cancer].
Hanai T; Matsumoto S; Shouji S; Usui Y; Tang XY; Kato Y; Iguchi M; Uemura H; Terachi T
Hinyokika Kiyo; 2009 Apr; 55(4):187-91. PubMed ID: 19462822
[TBL] [Abstract][Full Text] [Related]
8. Monotherapy versus combination drug therapy for the treatment of benign prostatic hyperplasia.
Logan YT; Belgeri MT
Am J Geriatr Pharmacother; 2005 Jun; 3(2):103-14. PubMed ID: 16129387
[TBL] [Abstract][Full Text] [Related]
9. Prostate cancer in African-American men: outcome following radiation therapy with or without adjuvant androgen ablation.
Zagars GK; Pollack A; Pettaway CA
Int J Radiat Oncol Biol Phys; 1998 Oct; 42(3):517-23. PubMed ID: 9806509
[TBL] [Abstract][Full Text] [Related]
10. Cathepsin B expression is similar in African-American and Caucasian prostate cancer patients.
Sinha AA; Morgan JL; Buus RJ; Ewing SL; Fernandes ET; Le C; Wilson MJ
Anticancer Res; 2007; 27(5A):3135-41. PubMed ID: 17970054
[TBL] [Abstract][Full Text] [Related]
11. Race and socioeconomic status are independently associated with benign prostatic hyperplasia.
Fowke JH; Murff HJ; Signorello LB; Lund L; Blot WJ
J Urol; 2008 Nov; 180(5):2091-6; discussion 2096. PubMed ID: 18804231
[TBL] [Abstract][Full Text] [Related]
12. Calculated fast-growing benign prostatic hyperplasia--a risk factor for developing clinical prostate cancer.
Hammarsten J; Högstedt B
Scand J Urol Nephrol; 2002; 36(5):330-8. PubMed ID: 12487736
[TBL] [Abstract][Full Text] [Related]
13. Progression, risk factors and subsequent medical management of symptomatic benign prostatic hyperplasia.
Pinto F; Racioppi M; Sacco E; Totaro A; Brescia A; Volpe A; Gardi M; Bassi PF
Arch Ital Urol Androl; 2009 Mar; 81(1):1-8. PubMed ID: 19499750
[TBL] [Abstract][Full Text] [Related]
14. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study.
Roehrborn CG; Siami P; Barkin J; Damião R; Major-Walker K; Nandy I; Morrill BB; Gagnier RP; Montorsi F;
Eur Urol; 2010 Jan; 57(1):123-31. PubMed ID: 19825505
[TBL] [Abstract][Full Text] [Related]
15. Effects of obesity and height on prostate-specific antigen (PSA) and percentage of free PSA levels among African-American and Caucasian men.
Fowke JH; Signorello LB; Chang SS; Matthews CE; Buchowski MS; Cookson MS; Ukoli FM; Blot WJ
Cancer; 2006 Nov; 107(10):2361-7. PubMed ID: 17031814
[TBL] [Abstract][Full Text] [Related]
16. Recruitment strategies and comparison of prostate cancer-specific clinical data on African-American and Caucasian males with and without family history.
Mandal DM; Sartor O; Halton SL; Mercante DE; Bailey-Wilson JE; Rayford W
Prostate Cancer Prostatic Dis; 2008; 11(3):274-9. PubMed ID: 18268528
[TBL] [Abstract][Full Text] [Related]
17. Improvements in benign prostatic hyperplasia-specific quality of life with dutasteride, the novel dual 5alpha-reductase inhibitor.
O'Leary MP; Roehrborn C; Andriole G; Nickel C; Boyle P; Höfner K
BJU Int; 2003 Aug; 92(3):262-6. PubMed ID: 12887480
[TBL] [Abstract][Full Text] [Related]
18. Socioeconomic status, healthcare density, and risk of prostate cancer among African American and Caucasian men in a large prospective study.
Major JM; Norman Oliver M; Doubeni CA; Hollenbeck AR; Graubard BI; Sinha R
Cancer Causes Control; 2012 Jul; 23(7):1185-91. PubMed ID: 22674292
[TBL] [Abstract][Full Text] [Related]
19. Is the ratio of transition zone to total prostate volume higher in African-American men than in their Caucasian or Hispanic counterparts?
Kaplan SA; Reis RB; Staimen VB; Te AE
Br J Urol; 1998 Dec; 82(6):804-7. PubMed ID: 9883215
[TBL] [Abstract][Full Text] [Related]
20. Benign prostatic hyperplasia and prostate cancer: an overview for primary care physicians.
Sausville J; Naslund M
Int J Clin Pract; 2010 Dec; 64(13):1740-5. PubMed ID: 21070524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
